First-line treatment of EGFR mutation-positive non-small cell lung cancer (NSCLC) by gefitinib

e19088 Background: Gefitinib shows outstandingly high rates of clinical benefit in NSCLC pts with EGFR mutation and is better tolerable than conventional chemotherapy, therefore its consideration f...